Virus antibody dynamics in primary and secondary dengue infections

Journal of Mathematical Biology

Volumn 69, Issue 6-7, 2014, Pages 1773-1800

  Gujarati, Tanvi P ^a   Ambika, G ^b  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

^b INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

Antibody dependent enhancement; Correlation factor among serotypes; Humoral immune response; Stability analysis; Time delay

Indexed keywords

VIRUS ANTIBODY;

BIOLOGICAL MODEL; DENGUE; DENGUE VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; MATHEMATICAL COMPUTING; VIRUS LOAD;

ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; HUMANS; IMMUNITY, HUMORAL; MODELS, IMMUNOLOGICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; VIRAL LOAD;

EID: 84891360407     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-013-0749-4     Document Type: Article

References (60)

1. Agur Z, Mehr R (1992) Use of modelling for elucidating trypanotolerance: preliminary considerations. In: Perry BD, Hansen JW (eds) Modelling vector borne and other parasitic diseases. ILRAD, Nairobi
2. Ambika G, Dahanukar N (2009) Virus immune drug dynamics. In: Daniel M, Rajasekar S (eds) Nonlinear dynamics. Narosa Publication, New Delhi
3. Beauchamin CAA, Handel AA (2011) Review of mathematical models of influenza A infection within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11(suppl 1):S7
4. Bielefeldt-Ohmann H (1997) Pathogenesis of dengue virus disease: missing pieces in the jigsaw. Trends Microbiol 5:409–413
5. Chan KR, Zhang SLX, Tan HC, Chan YK, Chow A, Lim APC, Vasudevan SG, Hanson BJ, Ooib EE (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 108(30):12479–12484
6. Chaturvedi UC, Tandon P, Mathur A, Kumar A (1978) Host defence mechanisms against dengue virus infection of mice. J Gen Virol 39:293–302
7. Chen IC, Wang SM, Yu CK, Liu CC (2013) Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 202(4):259–265
8. Derouich M, Boutayeb A (2006) Dengue fever: mathematical modelling and computer simulation. Appl Math Comput 177:528–544
9. Dibrov BF, Livshits MA, Volkenstein MV (1977) Mathematical model of immune processes. J Theor Biol 65:609–631
10. Diekmann O, Heesterbeek JAP (2000) Mathematical epidemiology of infectious diseases, model builiding, analysis and interpretation. John Wiley, Chichester
11. Dietz K (1975) Transmission and control of arbovirus diseases. In: Ludwig D, Cooke KL (eds) Epidemiology. SIAM, Philadelphia, pp 104–121
12. Esteva L, Vargas C (1998) Analysis of a dengue disease transmission model. Math Biosci 15:131–151
13. Esteva L, Vargas C (1999) A model for dengue disease with variable human population. J Math Biol 38:220–240
14. Esteva L, Vargas C (2003) Coexistence of different serotypes of dengue virus. J Math Biol 46:31–47
15. Feng Z, Velasco-Hernandez JK (1997) Competative exclusion in vector host-model for the dengue fever. J Math Biol 35:523–544
16. Fink J, Gu F, Vasudevan SG (2006) Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 16:263–275
17. Fischer DB, Halstead SB (1970) Observations related to pathogenesis of dengue hemorrhagic fever, V. Examination of age specific sequential infection rates using a mathematical model. Yale J Biol Med 42:329–349
18. Fowler AC (1981) Approximate solution of a model of biological immune responses incorporating delay. J Math Biol 13:23–45
19. Garba SM, Gumel AB, Abu Baker MR (2008) Backward bifurcations in dengue transmission dynamics. Math Biosci 215:11–25
20. Gibbons RV, Vaughn DW (2002) Dengue: an escalating problem. Br Med J 324:1563–1566
21. Guzman MG, Kouri G, Valds L, Bravo J, Vzquez S, Halstead SB (2002) Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 11(4): 223–227
22. Halstead SB (1970) Observations related to pathogenesis of dengue haemorrhagic fever VI: hypothesis and discussion. Yale J Biol Med 42:350–362
23. Halstead SB (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239:476–481
24. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421–467
25. Halstead SB (2007) Dengue. Lancet 370:1644–1652
26. Halstead SB (2009) Antibodies determine virulence in dengue. Ann N Y Acad Sci 1171(Suppl. 1):E48–56
27. Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, Cropp CB, Effler P (2007) Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 20(4):672–675
28. Janeway CA, Travers P, Walport M, Shlomchik MJ (2001) Immunobiology: the immune system in health and disease, 5th edn. Garland Science, New York
29. Jindadamrongwech S, Thepparit C, Smith DR (2004) Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch Virol 149:915–927
30. Julander J, Perry ST, Shresta S (2011) Important advances in the field of anti-dengue virus research. Antivir Chem Chemother 21:105–116
31. Kinney RM, Huang CY (2001) Development of new vaccines against dengue fever and Japanese enchephalitis. Intervirology 44(2–3):176–197
32. Kitchen CMR, Yeghiazarian L, Hoh R, McCune JM, Sinclair E, Martin JN, Deeks SG (2011) Immune activation, Cd4+T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection. PLoS One 6:e21190
33. Klein P (1980) Mathematical models of antibody response. Folia Microbiol 25:430–438
34. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue haemorrhagic fever. Am J Trop Med Hyg 40:444–451
35. Kyle JL, Balsitis SB, Zhang L, Beatty RP, Harris E (2008) Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in mouse model. Virology 380(2):296–303
36. Lakshmanan M, Senthilkumar DV (2010) Dynamics of non-linear time delay systems. Springer-Verlag, Berlin
37. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu C (2001) Immunopathogenesis of dengue virus infection. J Biomed Sci 8:377–388
38. Lindenbach D, Rice CM (2001) Flaviviridae: the viruses and their replication. In: Knipe D, Howley P (eds) Fields virology. Lippincott, Philadelphia, pp 991–1041
39. Marchuk GM (1997) Mathematical modelling of immune response on infectious diseases. Kluwer Academic Publishers, Dordrecht
40. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587–619
41. Noisakran S, Perng GC (2008) Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med 233:401–408
42. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, New York
43. Nuraini N, Soewono E, Sidarto KA (2007) A mathematical model of dengue internal transmission process. J Indonesia Math Soc (MIHMI) 13–1:123–132
44. Nuraini N, Tasman H, Soewono E, Sidarto KA (2009) A with-in host dengue infection model with immune response. Math Comput Model 49:1148–1155
45. Porterfield JS (1986) Antibody-depenedent enhancement of viral infectivity. In: Maramorosch K (ed) Advances in virus research, vol 31. Academic Press, London, pp 335–355
46. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV (1998) Dengue and dengue haemorrhagic fever. Lancet 352:971–977
47. Rotham AL (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev 11:532–543
48. Rothman AL (2004) Dengue: defining protective versus pathologic immunity. J Clin Invest 113:946–951
49. Rothman AL, Ennis FA (1999) Immunopathogenesis of dengue haemorrhagic fever. Virology 257:1–6
50. Run Tao H, Innis BL, Nisalak A, Usawattanakul W, Wang S, Kalayanarooj S, Anderson R (1995) Antibodies that block virus attachment to vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45:451–461
51. Sabin AB (1959) Dengue. In: Rivers TM, Horsfall F (eds) Viral and rickettsial infections of man, 3rd edn, vol 361. Lippincott, Philadelphia
52. Science Daily (1998) Global warming would foster spread of dengue fever into some temperate regions. http://www.sciencedaily.com/releases/1998/03/980310081157.htm/. Accessed 2 September 2013
53. Scott TW, Morrison AC (2010) Vector dynamics and transmission of dengue virus: implications for dengue survelliance and prevention strategies. In: Rotham AL (ed) Dengue virus. Current topics in microbiology and immunology, vol 338. Springer, Berlin, pp 115–128
54. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, Marovich MA (2003) DC SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197:823–829
55. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181:2–9
56. Wahala WM, de Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3(12):2374–2395
57. WHO (2013) Dengue and dengue haemorrhagic fever. http://www.who.int/mediacentre/factsheets/fs117/en/. Accessed 6October 2013
58. World Health Organisation (WHO) and Special programme for Research and Training in Tropical Diseases (TDR) (2009) Dengue-guidelines for diagnosis, treatment, prevention and control (ISBN 9789241547871)
59. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS (2000) Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6:816–820
60. Zhou H, Deem MW (2006) Sculpting the immunological response to dengue fever by polytopic vaccination. Vaccine 24:2451–2459